New Blood Test Helps Detect Brain Injury in Minutes
|
By LabMedica International staff writers Posted on 11 Sep 2019 |

Image: The i-STAT Alinity system integrates with-patient testing directly into the patient-care pathway, accelerating time to treatment, improving quality and increasing access to care (Photo courtesy of Abbott).
After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein (GFAP) correlates with intracranial injury visible on computerized axial tomography (CT) scan. Some patients with suspected TBI with normal CT findings show pathology on magnetic resonance imaging (MRI).
Recently scientists have found that a handheld blood analyzer could help detect brain injury within 15 minutes using a commercial system that measures GFAP and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) proteins from the brain that are released into the blood after a brain injury, They assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings.
Neurologists at the University of California at San Francisco (San Francisco, CA, USA) and their associates enrolled patients with TBI who had a clinically indicated head CT scan within 24 hours of injury at 18 level 1 trauma centers in the USA. For this analysis, they included patients with normal CT findings (Glasgow Coma Scale score 13–15) who consented to venipuncture within 24 hours post injury and who had a MRI scan 7–18 days post injury. They compared MRI findings in these patients with those of orthopedic trauma controls and healthy controls recruited from the study sites.
Plasma GFAP concentrations (pg/mL) were measured using a prototype assay on a point-of-care platform, the hand-held blood analyzer, the i-STAT Alinity system. The scientists used receiver operating characteristic (ROC) analysis to evaluate the discriminative ability of GFAP for positive MRI scans in patients with negative CT scans over 24 hours (time between injury and venipuncture). The primary outcome was the area under the ROC curve (AUC) for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings within 24 hours of injury.
The team recruited between February 26, 2014, and June 15, 2018, 450 patients with normal head CT scans (of whom 330 had negative MRI scans and 120 had positive MRI scans), 122 orthopedic trauma controls, and 209 healthy controls. AUC for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings was 0·777 over 24 hours. Median plasma GFAP concentration was highest in patients with CT-negative and MRI-positive findings (414.4 pg/mL), followed by patients with CT-negative and MRI-negative findings (74.0 pg/mL), orthopedic trauma controls (13.1 pg/mL), and healthy controls (8.0 pg/mL, all comparisons between patients with CT-negative MRI-positive findings and other groups.
The authors concluded that analysis of blood GFAP concentrations using prototype assays on a point-of-care platform within 24 hours of injury might improve detection of TBI and identify patients who might need subsequent MRI and follow-up. The study was published on August 23, 2019, in the journal The Lancet Neurology.
Related Links:
University of California at San Francisco
Recently scientists have found that a handheld blood analyzer could help detect brain injury within 15 minutes using a commercial system that measures GFAP and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) proteins from the brain that are released into the blood after a brain injury, They assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings.
Neurologists at the University of California at San Francisco (San Francisco, CA, USA) and their associates enrolled patients with TBI who had a clinically indicated head CT scan within 24 hours of injury at 18 level 1 trauma centers in the USA. For this analysis, they included patients with normal CT findings (Glasgow Coma Scale score 13–15) who consented to venipuncture within 24 hours post injury and who had a MRI scan 7–18 days post injury. They compared MRI findings in these patients with those of orthopedic trauma controls and healthy controls recruited from the study sites.
Plasma GFAP concentrations (pg/mL) were measured using a prototype assay on a point-of-care platform, the hand-held blood analyzer, the i-STAT Alinity system. The scientists used receiver operating characteristic (ROC) analysis to evaluate the discriminative ability of GFAP for positive MRI scans in patients with negative CT scans over 24 hours (time between injury and venipuncture). The primary outcome was the area under the ROC curve (AUC) for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings within 24 hours of injury.
The team recruited between February 26, 2014, and June 15, 2018, 450 patients with normal head CT scans (of whom 330 had negative MRI scans and 120 had positive MRI scans), 122 orthopedic trauma controls, and 209 healthy controls. AUC for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings was 0·777 over 24 hours. Median plasma GFAP concentration was highest in patients with CT-negative and MRI-positive findings (414.4 pg/mL), followed by patients with CT-negative and MRI-negative findings (74.0 pg/mL), orthopedic trauma controls (13.1 pg/mL), and healthy controls (8.0 pg/mL, all comparisons between patients with CT-negative MRI-positive findings and other groups.
The authors concluded that analysis of blood GFAP concentrations using prototype assays on a point-of-care platform within 24 hours of injury might improve detection of TBI and identify patients who might need subsequent MRI and follow-up. The study was published on August 23, 2019, in the journal The Lancet Neurology.
Related Links:
University of California at San Francisco
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







